TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06445738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm A: Radiotherapy Omission
Description: Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B: Standard Treatment
Description: Ineligible for RT omission on study; includes management of MRI-detected lesions.
Study: NCT06536595

Intervention type: OTHER
Intervention: Scales
Description: Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
Study: NCT06455566

Intervention type: DEVICE
Intervention: Leadless pacemaker implantation through right internal jugular vein
Description: Leadless pacemaker implantation through right internal jugular vein
Study: NCT06585059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 injection + Almonertinib Mesilate Tablets
Description: TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug.
Study: NCT04401709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Capecitabine
Description: gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
Study: NCT05778227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethylene Diamine Tetra Acetic acid
Description: Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: smearOFF
Description: Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etidronic acid /sodium hypochlorite
Description: During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
Study: NCT06113718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Exercise (digital rectal stimulation, abdominal massage)
Description: The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet.
Study: NCT06468488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIEP flap surgery without drain
Description: Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP flap surgery with drains
Description: Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
Study: NCT05778227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maleic acid
Description: Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
Study: NCT05461885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
Study: NCT04496258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Induction
Description: Participants are expected to have a positive emotional response to the more positive beach scene.
Study: NCT05929040

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mindful cognitive intervention
Description: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindful cognitive intervention
Description: Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
Study: NCT05014139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Given into the bladder (intravesically)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Given into the bladder (intravesically)
Study: NCT04496258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Emotion Induction
Description: Participants are expected to have a neutral emotional response to the neutral office scene.
Study: NCT05389124

Intervention type: BEHAVIORAL
Intervention: Partial abstinence from oral hygiene
Description: One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
Study: NCT06242977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)
Description: The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control cream
Description: This intervention will be for the control group, a simple lotion cream.
Study: NCT06277778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taekwondo training with music therapy
Description: Taekwondo training with music therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Taekwondo training alone
Description: Taekwondo training without music therapy
Study: NCT05105035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime or meropenem
Description: Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime or meropenem
Description: Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-1801
Description: Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be prescribed placebo every 12 hours for Days 1-14.
Study: NCT05647733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low splanchnic blood volume restrictive fluid management strategy
Description: Hemodynamic goal-directed restrictive fluid management strategy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optimized cardiac output liberal fluid management strategy
Description: Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
Study: NCT06568627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx (EX-03)
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Study: NCT06440707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
Description: The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
Description: The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham patients will have cap and electrodes in place, but no stimulation will be delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
Study: NCT05430386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Description: Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy.
Study: NCT06568627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gel vehicle)
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study: NCT06567132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
Study: NCT05080218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Hold UPA x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Hold SQ ABA x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Hold SEC x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Hold TOF x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: Hold SQ TNFi x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab Injection
Description: Hold CAN TNFi x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Hold BAR x 2 weeks at time of COVID booster

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Hold IXE x 2 weeks at time of COVID booster
Study: NCT04989257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor-based dual-antiplatelet therapy
Description: Aspirin with ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel-based dual-antiplatelet therapy
Description: Aspirin with clopidogrel
Study: NCT04819932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1451
Description: DWC202008 DWC202009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1451
Description: DWC202008 DWC202009
Study: NCT05696015

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Description: Without telehealth education, this group has only postdischarge education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ampiled Education
Description: With telehealth education, in addition of discharge education.
Study: NCT06060314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative Approach
Description: Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative Approach
Description: Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative Approach
Description: Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Approach
Description: Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Approach
Description: Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Approach
Description: Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
Study: NCT05648097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baldachin
Description: Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures.
Study: NCT05775198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBMC immunomodulated with IFNt
Description: Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
Study: NCT05124873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisture Management Liner
Description: A prototype liner designed to reduce heat that builds up on the limb.
Study: NCT04877197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-HT
Description: Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
Study: NCT05405673

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal immunochemical test (FIT)
Description: A kind of stool test
Study: NCT06293417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
Description: Treatment group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose escalation of moderate-intensity statin
Description: Control group
Study: NCT03697954

Intervention type: DEVICE
Intervention: full stage implantation of sacral neuromodulation
Description: full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
Study: NCT05390866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: A single HIIT on a bicycle ergometer
Study: NCT06037889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Aspirin. Oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Clopidogrel. Oral administration.
Study: NCT05686408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-601 ER
Description: Patients will take 1 pill orally once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 1 pill orally once daily for 6 weeks.
Study: NCT06383364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Coordinator
Description: The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
Study: NCT06149637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional neck dissection approach
Description: .1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior neck dissection approach
Description: 1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve.
Study: NCT06359405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: drug safety simulation
Description: The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided.
Study: NCT06393361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide; Decitabine; Anti-PD-1 Antibody
Description: Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin, anti-PD-1 antibody.
Description: Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Study: NCT04848766

Intervention type: DRUG
Intervention: De-escalation Treatment Strategy of dual antiplatelet therapy
Description: Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
Study: NCT05872035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Software
Description: Amplification settings established by algorithm and further adjusted by participants per their preference

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: by Audiologist
Description: Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
Study: NCT06592313

Intervention type: PROCEDURE
Intervention: Intubation
Description: Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
Study: NCT05540886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH CLEAN
Description: The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities.
Study: NCT06654999

Intervention type: DEVICE
Intervention: Deep Ensemble for the Recognition of Malignancy (DERM)
Description: DERM variants + and DS